Business
Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026
Abbott (NYSE: ABT) today announced new late-breaking data from four trials that demonstrate strong clinical outcomes within its pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios to treat heart rhythm disorders.
About this update from Abbott Laboratories
[{"type":"list","items":[{"val":[{"type":"text","content":"Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field ablation and novel cardiac pacing portfolios","length":193,"tagName":"p"}]},{"val":[{"type":"text","content":"Six-month results from the FlexPulse IDE study for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, reveal positive outcomes for treating complex AFib cases","length":167,"tagName":"p"}]},{"val":[{"type":"text","content":"New data from the Volt CE Mark Extension Cohort trial for the Volt™ PFA System, demonstrate the strong safety, efficacy and efficiency of treatment of AFib cases for posterior wall ablation","length":189,"tagName":"p"}]},{"val":[{"type":"text","content":"Two new conduction system pacing studies showcase initial results of Abbott's investigational UltiSynq™ CSP implantable cardioverter-defibrillator lead and a first-in-human evaluation of the investigational AVEIR™ CSP leadless pacemaker system","length":247,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":796,"olType":false},{"type":"text","content":"ABBOTT PARK, Ill., April 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new late-breaking data from four trials that demonstrate strong clinical outcomes within its pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios to treat heart rhythm disorders.","length":284,"tagName":"p"},{"type":"text","content":"The data include six-month results from the FlexPulse IDE study, which examines treating complex atrial fibrillation (AFib) cases with the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, as well as new clinical evidence for posterior wall ablation with the Volt™ PFA System. Data were also presented for Abbott's ASCEND CSP IDE trial for the company's investigational UltiSynq™ CSP implantable cardioverter-defibrillator (ICD) lead, as well as a first-in-human evaluation of the LEAP2 chronic early feasibility trial for the investigational AVEIR™ CSP leadless pacemaker system.","length":589,"tagName":"p"},{"type":"text","content":"Positive results support TactiFlex Duo Ablation Catheter, Sensor EnabledNew six-month data from the FlexPulse IDE study provide early insights showing positive patient outcomes with Abbott's TactiFlex Duo Ablation Catheter, Sen...